Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational aurora A kinase inhibitor MLN8237 (Alisertib)

Molecular Cancer Therapeutics

Volumn 13, Issue 9, 2014, Pages 2170-2183

  Huck, Jessica J ^a   Zhang, Mengkun ^a   Mettetal, Jerome ^a   Chakravarty, Arijit ^a   Venkatakrishnan, Karthik ^a   Zhou, Xiaofei ^a   Kleinfield, Rob ^a   Hyer, Marc L ^a   Kannan, Karuppiah ^a   Shinde, Vaishali ^a   Dorner, Andy ^a   Manfredi, Mark G ^a   Shyu, Wen Chyi ^a   Ecsedy, Jeffrey A ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; ANTINEOPLASTIC AGENT; AURORA A KINASE; AZEPINE DERIVATIVE; DOCETAXEL; PACLITAXEL; PYRIMIDINE DERIVATIVE; TAXOID;

ANIMAL; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DRUG ADMINISTRATION; FEMALE; HUMAN; MOUSE; NEOPLASMS, EXPERIMENTAL; SCID MOUSE; TRANSLATIONAL RESEARCH; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; AURORA KINASE A; AZEPINES; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; PYRIMIDINES; TAXOIDS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84907225950     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0027     Document Type: Article

References (52)

1. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5 Suppl 6:S3-6.
2. Yamada HY, Gorbsky GJ. Spindle checkpoint function and cellular sensitivity to antimitotic drugs. Mol Cancer Ther 2006; 5:2963-9.
3. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14:111-22.
4. Ecsedy JA, Chakravarty A, Manfredi M., D'Amore N. Current and next generation antimitotic therapies in cancer therapy. In: Frank DA, editor. Signaling pathways in cancer pathogenesis and therapy. New York, NY: Springer Publishing; 2012 p. 5-22
5. Green MR, Woolery JE, Mahadevan D. Update on Aurora kinase targeted therapeutics in oncology. Expert Opin Drug Discov 2011; 6:291-307.
6. Kelly KR, Ecsedy J, Mahalingam D., Nawrocki ST, Padmanabhan S, Giles FJ, et al. Targeting aurora kinases in cancer treatment. Curr Drug Targets 2011; 12:2067-78.
7. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007; 120:2987-96.
8. Bischoff JR, Plowman GD. The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999; 9:454-9.
9. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4:842-54.
10. Giet R, Petretti C, Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol 2005; 15:241-50.
11. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 2010; 10:825-41.
12. Glover DM, Leibowitz MH, McLean D.A., Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995; 81:95-105
13. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, et al. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007; 27:4513-25.
14. Kaestner P, Stolz A, Bastians H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 2009; 8:2046-56.
15. Katayama H, Zhou H, Li Q., Tatsuka M, Sen S. Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and protein phos-phatase 1 through mitotic cell division cycle. J Biol Chem 2001; 276: 46219-24.
16. Marumoto T, Honda S, Hara T., Nitta M, Hirota T, Kohmura E., et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003; 278:51786-95.
17. Sasai K, Parant JM, Brandt M.E., Carter J., Adams HP, Stass SA, et al. Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene 2008; 27:4122-7
18. Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM, Stringer B, et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 2010; 8:373-84.
19. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L., Zhang M, Hoar KM, et al. Characterization of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo phar-macodynamic assays. Clin Cancer Res 2011; 17:7614-24.
20. Basso AD, Liu M, Gray K., Tevar S, Lee S, Liang L., et al. SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors. Cancer Chemother Pharmacol 2011; 68:923-33.
21. Curry J, Angove H, Fazal L., Lyons J, Reule M, Thompson N., et al. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle 2009; 8:1921-9.
22. Scharer CD, Laycock N, Osunkoya A.O., Logani S., McDonald JF, Benigno BB, et al. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 2008; 6:79.
23. Hata T, Furukawa T, Sunamura M., Egawa S, Motoi F, Ohmura N., et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005; 65:2899-905.
24. Mazumdar A, Henderson YC, El-Naggar AK, Sen S., Clayman GL. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 2009; 31:625-34.
25. Qi W, Cooke LS, Liu X, Rimsza L., Roe DJ, Manziolli A, et al. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 2011; 81:881-90.
26. Shimomura T, Hasako S, Nakatsuru Y., Mita T, Ichikawa K, Kodera T., et al. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther 2010; 9:157-66.
27. Kumano M, Miyake H, Terakawa T., Furukawa J, Fujisawa M. Suppressed tumour growth and enhanced chemosensitivity by RNA interference targeting Aurora-A in the PC3 human prostate cancer model. BJU Int 2010; 106:121-7.
28. Lin YG, Immaneni A, Merritt W.M., Mangala LS, Kim SW, Shahzad MM, et al. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 2008; 14:5437-46.
29. Tanaka E, Hashimoto Y, Ito T., Kondo K, Higashiyama M, Tsunoda S., et al. The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res 2007; 13:1331-40.
30. Jeet V, Russell PJ, Verma N.D., Khatri A. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. Curr Cancer Drug Targets 2012; 12: 144-63
31. Wysong DR, Chakravarty A, Hoar K, Ecsedy JA. The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle 2009; 8:876-88.
32. Jiang Y, Zhang Y, Lees E., Seghezzi W. AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a micro-tubule destabilizer. Oncogene 2003; 22:8293-301.
33. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-a amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3:51-62.
34. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16 Suppl 1:1-11.
35. Chakravarty A, Shinde V, Tabernero J., Cervantes A, Cohen RB, Dees E.C., et al. Phase I assessment of new mechanism-based pharmaco-dynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res 2011; 71:675-85.
36. Dees EC, Infante JR, Cohen R.B., O'Neil BH, Jones S, von Mehren M, et al. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 67:945-54.
37. Thummel KE, Shen DD, Isoherranen N. Appendix II: design and optimization of dosage regimens: pharmacokinetic data. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York, NY: McGraw-Hill; 2010 p. 1891
38. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venka-takrishnan K, et al. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacody-namics, and bioavailability of two oral formulations. Clin Cancer Res 2012; 18:4775-84.
39. Cervantes A, Elez E, Roda D., Ecsedy J, Macarulla T, Venkatakrishnan K., et al. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora A kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 4764-74.
40. Falchook GS, Goff BA, Kurzrock R, Gray H.J., Martin LP, Coleman RL, et al. Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): Phase I results. J Clin Oncol 2012; 30:15s, (suppl; abstr 5021).
41. Fennelly D, Aghajanian C, Shapiro F., O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15:187-92.
42. Rose PG, Smrekar M, Fusco N. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. Gynecol Oncol 2005; 96:296-300.
43. Bookman MA. Dose-dense chemotherapy in advanced ovarian cancer. Lancet 2009; 374:1303-5.
44. Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opin Biol Ther 2012; 12:1415-21.
45. Barginear MF, John V, Budman DR. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med 2012; 18:1473-9.
46. Matulonis UA, Sharma S, Ghamande S., Gordon MS, Del Prete SA, Ray-Coquard I, et al. Phase II study of MLN8237 (alisertib), an inves-tigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 2012; 127:63-9.
47. Mosse YP, Lipsitz E, Fox E., Teachey DT, Maris JM, Weigel B, et al. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res 2012; 18:6058-64.
48. Matulonis UA, Pereira L, Liu J., Lee H, Lee J, Whalen C., et al. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol 2012; 126:41-6.
49. Gonzalez-Angulo AM, Hortobagyi GN. Optimal schedule of paclitaxel: weekly is better. J Clin Oncol 2008; 26:1585-7.
50. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 2010; 7:575-82.
51. Friberg LE, Henningsson A, Maas H., Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20:4713-21.
52. Le K, Yu L, Manfredi M., Ecsedy J, Silverman L, Cardoza K., et al. Evaluation of optimal dosing regimens for investigational drug MLN8237, an Aurora A kinase inhibitor, in combination with docetaxel through pharmacokinetic-pharmacodynamic (PK-PD) modeling of hematological toxicity. Clin Pharmacol Ther 2011; 89:s58-9 (suppl; abstr PII-67).